The $6.5 Billion Biodefense Market by 2025 - Small Pox is Expected to Be the Fastest Growing Product Segment

4/24/2019, 12:47 PM (Source: GlobeNewswire)

Dublin, April 24, 2019 (GLOBE NEWSWIRE) -- The "Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Small Pox, Botulism, Radiation/Nuclear), By Region (North America, Latin America, Europe, Asia Pacific, MEA), And Segment Forecasts, 2019 - 2025" report has been added to's offering.

The global biodefense market size is expected to reach USD 6.5 billion by 2025, growing at a CAGR of 4.5% over the forecast period.

The market is majorly driven by rising focus of the public agencies on mitigating the risk of Chemical, Biological, Radiological and Nuclear (CBRN) threats and increased funding for biodefense. Biomedical Advanced Research and Development Authority (BARDA), National Interagency Confederation for Biological Research (NICBR), and National Institute of Allergy and Infectious Diseases (NIAID) are major organizations that provide financial support for biodefense research and stockpiling in U.S.

Ongoing research for the development of vaccinations and anti-toxins against biological threats, such as Zika virus, is also one of the key drivers contributing to the market growth. For instance, Ohio State University is undertaking a progressive research to develop a vaccine against the Zika virus that has proven beneficial results in the mice models. According to a survey, in Brazil, around 2,952 confirmed cases of Zika-related microcephaly in newborns were reported. Thus, rising risk of biological threats and subsequently rising R&D funding are augmenting the growth of this market.

Presence of EUA policy in U.S. is also positively impacting the market growth. The EUA policy empowers FDA Commissioners to allow and authorize the usage of a medical product(s) for commercial use, at the time of a declared emergency in the country posing a threat to public health, that are currently unapproved or an application of an approved medical product for a particular indication is unapproved by the FDA. The government agencies issued the EUA policy for antiviral drugs to fight against diseases, such as Zika virus infection and swine flu.

Further key findings from the study suggest:

  • Anthrax held the largest share in 2018 owing to increased investments by government agencies and collaborations between public and private companies to develop and stockpile anthrax vaccines
  • Others segment consists of chemical and biological products. It accounted for the second-largest revenue share in 2018
  • Small pox is expected to be the fastest-growing product segment of the global biodefense market over the forecast period
  • North America was the largest regional market owing to favorable government initiatives and funding in the field of biodefense
  • Europe is expected to witness the maximum growth rate from 2019 to 2025 on account of growing focus of the European countries to enhance the preparedness against CBRN threats
  • Some of the key companies in the global market include PharmAthene, Inc.; Emergent BioSolutions, Inc.; SIGA Technologies, Inc.; and Xoma Corporation

Key Topics Covered

Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.4 Information Analysis
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing

Chapter 2 Executive Summary
2.1 Biodefense Market Outlook, 2014 - 2025 (USD Million)
2.2 Biodefense Segment Outlook, 2014 - 2025 (USD Million)
2.3 Biodefense Competitive Insights Outlook, 2014 - 2025 (USD Million)

Chapter 3 Biodefense Market Variables, Trends & Scope
3.1 Biodefense Market Lineage Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis
3.4 User Perspective Analysis
3.5 List of Key End-users
3.6 Technology Overview
3.7 Regulatory Framework
3.8 Biodefense Market Dynamics
3.9 Biodefense Market Analysis Tools

Chapter 4 Biodefense Market- Competitive Analysis
4.1 Recent developments & impact analysis, by key market participants
4.2 Company/Competition Categorization
4.3 Vendor Landscape
4.4 Public Companies
4.5 Private Companies

Chapter 5 Biodefense Market: Product Estimates & Trend Analysis
5.1 Definition & Scope
5.2 Product Market Share Analysis, 2018 & 2025
5.3 Segment Dashboard
5.4 Global Biodefense Market Revenue Estimates and Forecasts, by Product, 2014 - 2025 (USD Million)

Chapter 6 Biodefense Market: Regional Estimates & Trend Analysis, By Product
6.1 Regional Biodefense Market Snapshot, 2018 & 2025 (market size, CAGR, top verticals, top trends)
6.2 Leading Players, by Region, 2018
6.3 North America
6.4 Europe
6.5 Asia Pacific
6.6 Latin America
6.7 MEA
6.8 SWOT Analysis, by Factor

Chapter 7 Competitive Landscape
7.1 Company Profiles
7.1.1 Xoma Corporation
7.1.2 Altimune Inc. (PharmAthene Inc.)
7.1.3 Emergent Biosolutions Inc.
7.1.4 Dynavax Technologies Corporation
7.1.5 SIGA Technologies Inc.
7.1.6 Elusys Therapeutics Inc.
7.1.7 B.Ichor Medical Systems
7.1.8 Dynport Vaccine Company LLC
7.1.9 Cleveland Biolabs
7.1.10 Bavarian Nordic
7.1.11 Achaogen Inc.
7.1.12 Nanotherapeutics Inc.
7.1.13 Alnylam Pharmaceuticals Inc.
7.2 List of other companies

For more information about this report visit

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Biodefense 


Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.